Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| Flexion Therapeutics IncFLXN · Entity 16545 | Director | June 10, 2020 | June 12, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, CFO & CBO | May 11, 2020 | July 10, 2020 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 07, 2022 | June 10, 2022 |
| Vor Biopharma Inc.VOR · Entity 4763 | CFO | December 05, 2025 | December 09, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Flexion Therapeutics Inc
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 4,500 · Balance 4,500 F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 7,000 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Grant · Acquired 7,000 · Balance 7,000 F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant.
Sarepta Therapeutics, Inc.
Report date May 11, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,260 |
Ending reported balance
After 2020-07-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-05-11 · Gift · Disposed 20,425 · Balance 16,454 F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts. Row 2 · 2020-07-08 · Exercise / conversion · Acquired 2,385 · Balance 18,839 Row 3 · 2020-07-08 · Exercise / conversion · Acquired 218 · Balance 19,057 Row 4 · 2020-07-08 · Exercise / conversion · Acquired 1,203 · Balance 20,260 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-07-08 · Exercise / conversion · Disposed 2,385 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-08 · Exercise / conversion · Disposed 218 · Balance 0 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.63 · Expires 2027-03-10 | Direct | 0 |
Reported balance
After 2020-07-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-08 · Exercise / conversion · Disposed 1,203 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 12,012 |
Reported balance
Holding disclosure · report date 2020-05-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 12,012 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction involved a gift of shares of common stock by the reporting person to family trusts.
Spyre Therapeutics, Inc.
Report date June 07, 2022 · Filed June 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2032-06-06 | Direct | 43,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 43,000 · Balance 43,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Vor Biopharma Inc.
Report date December 05, 2025 · Filed December 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 694,137 · Balance 0 F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split. F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.80 · Expires 2035-12-04 | Direct | 1,388,274 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Grant · Acquired 1,388,274 · Balance 1,388,274 F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above. F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split.
F2: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025.
F3: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above.
F4: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 21:42 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $51.84 | $0.00 |
DisclosureSEC source: 0001193125-26-264286 · ownership.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 13:00 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 1,388,274 | $0.00 Strike: $17.80 | $0.00 |
DisclosureSEC source: 0001511034-25-000006 · form4-12092025_081205.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,388,274 Underlying: Common Stock · 1,388,274 shares Expires 2035-12-04 F3 · derivative.exercise_price: The exercise price per share of common stock subject to the option will be (a) $17.80 per share, or (b) to the extent the option is exercised following the end of the Retention Period, $8.18 per share, the closing price of a share of common stock on the grant date (December 5, 2025). The "Retention Period" begins on December 5, 2025 and ends on the earlier of (i) December 5, 2027 or (ii) a Change in Control (as defined in the 2021 Plan) during the Reporting Person's Continuous Service (as defined in the 2021 Plan) with the Issuer. In the event that the Reporting Person's Continuous Service terminates for any reason or no reason prior to the end of the Retention Period, the exercise price per share of Common Stock subject to the Option will be as set forth in clause (a) above. F4 · derivative.exercise_date: 1/4th of the shares underlying the option vest on July 1, 2026, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 13:00 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerCommon Stock | 694,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001511034-25-000006 · form4-12092025_081205.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On September 18, 2025, the Issuer effected a 1-for-20 reverse stock split. The share counts herein reflect the reverse stock split. F2 · shares: On December 5, 2025, the Issuer's Compensation Committee of the Board of Directors approved the cancellation of the previously awarded grant of 694,137 restricted stock units, which was reported in a Form 4 filed on July 10, 2025. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:51 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 13,882,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019640 · form4-07102025_080725.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,882,750 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. 1/4th of the RSUs vest on July 1, 2026, with the remainder vesting in equal quarterly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $38.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083269 · ownership.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $54.06 | $0.00 |
DisclosureSEC source: 0000950170-24-067329 · ownership.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 01:18 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035687 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:26 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-039231 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 1,203 | $32.63 Strike: $32.63 | $39,253.89 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · derivative · entry 8 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,203 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 218 | $13.71 Strike: $13.71 | $2,988.78 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · derivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 218 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,385 | $13.71 Strike: $13.71 | $32,698.35 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · derivative · entry 6 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,385 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,203 | $32.63 | $39,253.89 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 218 | $13.71 | $2,988.78 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,385 | $13.71 | $32,698.35 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 16:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 7,000 | $0.00 Strike: $11.88 | $0.00 |
DisclosureSEC source: 0001209191-20-036257 · doc4.xml · derivative · entry 2 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 16:17 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036257 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:28 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 28,100 | $0.00 Strike: $8.89 | $0.00 |
DisclosureSEC source: 0001209191-20-035519 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires 2030-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2020 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 11, 2020 Filed Jul 10, 2020 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GiftCommon Stock | 20,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042060 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,454 F1 · kind: This transaction involved a gift of shares of common stock by the reporting person to family trusts. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014223 · doc4.xml · derivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014223 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,879 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 14,723 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 14 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,277 Underlying: Common Stock · 14,723 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 21,875 | $0.00 Strike: $32.63 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 13 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,874 Underlying: Common Stock · 21,875 shares Expires 2027-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 69,479 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 12 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,479 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 10,466 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 11 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,466 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 4,138 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,633 Underlying: Common Stock · 4,138 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 4,319 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,085 Underlying: Common Stock · 4,319 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 125,000 | $125.50 | $15,687,500.00 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,179 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 14,723 | $34.92 | $514,127.16 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 6 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 21,875 | $32.63 | $713,781.25 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 69,479 | $29.03 | $2,016,975.37 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 10,466 | $23.85 | $249,614.10 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 4,138 | $13.71 | $56,731.98 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,636 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 4,319 | $13.71 | $59,213.49 |
DisclosureSEC source: 0001209191-19-061048 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| August 22, 2019 Filed Aug 22, 2019 23:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GiftCommon Stock | 42,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047178 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,179 F2 · kind: This transaction involved a gift of shares of common stock by the reporting person to a family trust. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 23:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Appreciation Right · Derivative | 100,000 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-047178 · doc4.xml · derivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes. F3 · derivative.exercise_date: 25% of the shares subject to the SAR vested on the first anniversary measured from November 5, 2012 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vested in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the SAR were fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 23:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 57,465 | $101.50 | $5,832,697.50 |
DisclosureSEC source: 0001209191-19-047178 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,714 F1 · kind: This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 23:20 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 100,000 | $23.85 | $2,385,000.00 |
DisclosureSEC source: 0001209191-19-047178 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction involved the exercise of a stock appreciation right ("SAR") relating to 100,000 shares of common stock, upon which the reporting person received shares of common stock net of shares of common stock withheld as payment of the exercise price and withholding taxes. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 260 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · derivative · entry 11 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218 Underlying: Common Stock · 260 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 985 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · derivative · entry 10 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,385 Underlying: Common Stock · 985 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,625 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · derivative · entry 9 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,625 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 3,021 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · derivative · entry 8 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,021 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 2,863 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · derivative · entry 7 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,863 shares Expires 2023-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 260 | $13.71 | $3,564.60 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · nonDerivative · entry 5 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 985 | $13.71 | $13,504.35 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · nonDerivative · entry 4 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,625 | $13.90 | $36,487.50 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · nonDerivative · entry 3 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 3,021 | $29.03 | $87,699.63 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| August 15, 2019 Filed Aug 15, 2019 20:33 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 2,863 | $34.92 | $99,975.96 |
DisclosureSEC source: 0001209191-19-046150 · doc4.xml · nonDerivative · entry 1 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person executed a cash exercise of options without a subsequent sale of the underlying common stock. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:10 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001209191-19-038459 · doc4.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 20:50 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 12,400 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001567619-19-013072 · doc1.xml · derivative · entry 1 Mahatme Sandesh · CIK 0001511034 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2029-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2019 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| March 28, 2019 Filed Mar 30, 2019 00:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,953 | $118.68 | $350,462.04 |
DisclosureSEC source: 0001209191-19-021878 · doc4.xml · nonDerivative · entry 2 Mahatme Sandesh · CIK 0001511034 · EVP, CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,425 F2 · price: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of performance-based restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.